SHKBP1 Antibody

What is SHKBP1 and what cellular functions does it regulate?

SHKBP1 (SH3KBP1 binding protein 1) is a 76 kDa protein that plays a critical role in regulating EGFR signaling pathways. It functions by inhibiting CBL-SH3KBP1 complex-mediated down-regulation of EGFR signaling through sequestration of SH3KBP1 . SHKBP1 contains two PXXXPR motifs (PSPSPR at aa 618-623 and PTPAPR at aa 679-684) that allow it to bind to the SH3 domains of CIN85 . This binding prevents CIN85's interaction with c-Cbl and inhibits the translocation of CIN85 to EGFR-containing vesicles upon EGF stimulation, ultimately reducing EGFR degradation and enhancing EGF-induced signaling activity .

What are the key specifications for commercially available SHKBP1 antibodies?

SHKBP1 antibodies are predominantly rabbit polyclonal antibodies designed for various research applications. Key specifications include:

How should researchers validate SHKBP1 antibody specificity?

Validation of SHKBP1 antibody specificity is crucial for obtaining reliable experimental results:

• Western blot validation: Confirm the presence of a single band at the expected 76 kDa molecular weight using positive control samples such as A431 cells .

• Genetic knockdown validation: Use siRNA or CRISPR-Cas9 to reduce SHKBP1 expression and verify corresponding reduction in antibody signal.

• Overexpression validation: Transfect cells with SHKBP1 expression vectors and confirm increased antibody signal.

• Cross-validation using multiple antibodies: Compare detection patterns using antibodies targeting different epitopes of SHKBP1.

• Positive control tissues/cells: Use validated samples known to express SHKBP1:

  • A431 cells for WB

  • A549 cells for IF/ICC

  • Human colon, liver cancer, or lung adenocarcinoma tissues for IHC

What are the optimal protocols for Western blot detection of SHKBP1?

For optimal Western blot detection of SHKBP1, researchers should follow these guidelines:

• Sample preparation:

  • Prepare whole cell lysates from appropriate cell types (A431 cells show positive expression)

  • Use fresh lysates with protease inhibitors to prevent degradation

• SDS-PAGE conditions:

  • Use 7.5% SDS-PAGE for optimal separation

  • Load 30 μg of whole cell lysate per lane

• Transfer and blocking:

  • Standard transfer to PVDF or nitrocellulose membrane

  • Block with appropriate buffer (typically containing BSA or milk)

• Antibody incubation:

  • Primary antibody dilution: 1:500-1:1000 or as specified by manufacturer

  • Incubate overnight at 4°C for optimal results

• Detection:

  • Use appropriate HRP-conjugated secondary antibody

  • Expected band size: 76 kDa

• Controls:

  • Include positive control (A431 cell lysate)

  • Include molecular weight marker to confirm band size

How should researchers optimize immunofluorescence protocols for SHKBP1 detection?

For optimal immunofluorescence detection of SHKBP1:

• Cell preparation:

  • Use appropriate cell types (A549 cells have shown positive IF/ICC for SHKBP1)

  • Grow cells on glass coverslips to appropriate confluence

• Fixation and permeabilization:

  • Fixation methods: 4% paraformaldehyde for 15-20 minutes at room temperature

  • Permeabilization: 0.1-0.5% Triton X-100 for 5-10 minutes

• Blocking and antibody incubation:

  • Block with 10% normal goat serum

  • Primary antibody dilution: 1:200-1:800

  • Incubate overnight at 4°C for best results

• Visualization:

  • Use appropriate fluorophore-conjugated secondary antibodies

  • Counterstain nuclei with DAPI

  • Mount with anti-fade mounting medium

• Controls:

  • Include negative controls (primary antibody omission)

  • If possible, include SHKBP1 knockdown cells as specificity controls

What are the best practices for immunohistochemical detection of SHKBP1 in tissue samples?

For immunohistochemical detection of SHKBP1:

• Tissue preparation:

  • Use formalin-fixed, paraffin-embedded (FFPE) tissue sections

  • Section thickness: typically 4-5 μm

• Antigen retrieval:

  • Heat-mediated antigen retrieval in EDTA buffer (pH 8.0)

  • This step is critical for exposing epitopes masked by fixation

• Blocking and antibody incubation:

  • Block with 10% goat serum

  • Primary antibody dilution: 1:50-1:200

  • Incubate overnight at 4°C (typically using 2 μg/ml concentration)

• Detection system:

  • Use appropriate detection systems such as HRP-conjugated secondary antibodies

  • Develop with DAB as the chromogen

  • Counterstain with hematoxylin

• Validated positive tissues:

  • Diffuse large B-cell lymphoma of human intestine

  • Human colon tissue

  • Human liver cancer tissue

  • Human lung adenocarcinoma tissue

How can researchers use SHKBP1 antibodies to study protein-protein interactions?

SHKBP1 antibodies can be powerful tools for studying protein-protein interactions:

• Co-immunoprecipitation (Co-IP):

  • Use 6 μg of SHKBP1 antibody per IP reaction

  • Prepare cell lysates using mild lysis buffers (e.g., NETN buffer)

  • Immunoprecipitate SHKBP1 and probe for interacting partners like CIN85

  • Perform reciprocal Co-IP using antibodies against suspected binding partners

  • Include appropriate controls (IgG control, input samples)

• Proximity Ligation Assay (PLA):

  • Use SHKBP1 antibodies in conjunction with antibodies against potential binding partners

  • This technique allows visualization of protein interactions in situ with subcellular resolution

  • Particularly useful for studying the interaction between SHKBP1 and CIN85

• FRET/BRET analysis:

  • Use antibodies to validate interactions identified through these biophysical techniques

  • Confirm co-localization before undertaking these more specialized approaches

• Pull-down assays with mutants:

  • Generate SHKBP1 mutants (e.g., R623A, R684A, or double mutant R623A/R684A) to study binding domains

  • Use antibodies to detect interactions with various mutants

  • This approach can reveal the specific domains required for protein-protein interactions

How can researchers investigate the role of SHKBP1 in EGFR signaling pathways?

To investigate SHKBP1's role in EGFR signaling:

• Stimulation experiments:

  • Treat cells with EGF at various time points and concentrations

  • Use SHKBP1 antibodies to track expression and localization changes

  • Determine whether SHKBP1-CIN85 interaction changes upon EGF stimulation (research indicates it does not)

• Signaling dynamics analysis:

  • Use SHKBP1 antibodies in combination with phospho-specific antibodies targeting EGFR and downstream effectors

  • Monitor how SHKBP1 knockdown or overexpression affects the phosphorylation status of signaling components

• Subcellular fractionation:

  • Use SHKBP1 antibodies to track protein distribution across cellular compartments following EGF stimulation

  • Determine if SHKBP1 prevents translocation of CIN85 to EGFR-containing vesicles

• Receptor trafficking studies:

  • Combine SHKBP1 immunofluorescence with endosomal markers

  • Track how manipulation of SHKBP1 levels affects EGFR internalization and degradation

• Functional readouts:

  • Assess how SHKBP1 manipulation affects EGF-induced transcriptional activity

  • Measure EGFR degradation rates in the presence and absence of SHKBP1

What are the considerations for using SHKBP1 antibodies in multiplex immunostaining approaches?

For multiplex immunostaining with SHKBP1 antibodies:

• Antibody compatibility:

  • Ensure antibodies are from different host species or use directly conjugated antibodies

  • Validate absence of cross-reactivity between detection systems

• Sequential staining protocols:

  • If using antibodies from the same species, consider sequential staining with thorough blocking between steps

  • Test for signal loss/epitope destruction during multiple rounds of staining

• Spectral separation:

  • Choose fluorophores with minimal spectral overlap when using fluorescent detection

  • Include appropriate single-stain controls for spectral unmixing

• Epitope considerations:

  • Ensure antigen retrieval conditions are compatible with all target antigens

  • Some epitopes may be sensitive to specific retrieval methods

• Signal amplification:

  • Consider tyramide signal amplification for weak signals

  • Balance amplification strength to achieve comparable signal intensity across targets

• Controls:

  • Include single-color controls for accurate compensation

  • Use both positive and negative tissue controls for each marker

How should researchers address common technical issues when using SHKBP1 antibodies?

Common technical issues and their solutions include:

• Non-specific bands in Western blot:

  • Increase blocking time and concentration

  • Optimize antibody dilution (try 1:1000 as a starting point)

  • Increase wash duration and number of washes

  • Use freshly prepared samples with protease inhibitors

  • Validate with positive control (A431 cells)

• Weak or no signal:

  • Ensure the antibody reactivity matches your species (human, mouse, rat)

  • Increase protein loading (try 30 μg as recommended)

  • Reduce antibody dilution within recommended range

  • Optimize antigen retrieval for IHC/IF (EDTA buffer, pH 8.0 is recommended)

  • Extend primary antibody incubation time (overnight at 4°C)

• High background in immunostaining:

  • Increase blocking time using 10% normal goat serum

  • Dilute primary antibody further (within recommended range)

  • Add additional wash steps

  • Use appropriate negative controls (secondary antibody only, isotype control)

• Inconsistent immunoprecipitation results:

  • Optimize lysis conditions to preserve protein-protein interactions

  • Adjust antibody amount (6 μg per reaction has been effective)

  • Pre-clear lysates to reduce non-specific binding

  • Ensure antibody is suitable for IP applications

How can researchers interpret varying expression patterns of SHKBP1 across different cell lines and tissues?

When encountering varying SHKBP1 expression patterns:

• Biological relevance assessment:

  • Consider tissue-specific functions of SHKBP1

  • Correlate with EGFR expression/activity, as SHKBP1 regulates EGFR signaling

  • Evaluate expression in normal vs. pathological contexts (SHKBP1 has been detected in several cancer tissues)

• Technical considerations:

  • Verify using multiple antibodies targeting different epitopes

  • Confirm at both protein (WB, IHC) and mRNA (qPCR) levels

  • Consider effects of sample preparation on epitope availability

• Comparative analysis:

  • Systematically compare expression across tissue/cell panels

  • Document subcellular localization differences

  • Consider post-translational modifications affecting antibody recognition

• Context-dependent regulation:

  • Evaluate how growth conditions affect expression

  • Consider cell cycle-dependent regulation

  • Assess effects of relevant signaling pathway activation (e.g., EGF stimulation)

How can researchers use SHKBP1 antibodies to investigate potential cross-talk between EGFR and inflammatory signaling pathways?

To investigate potential cross-talk:

• Stimulation experiments:

  • Treat cells with both EGF and inflammatory stimuli (e.g., LPS, cytokines)

  • Use SHKBP1 antibodies to track expression and localization changes

  • Determine if inflammatory conditions alter SHKBP1's interaction with CIN85

• Co-immunoprecipitation studies:

  • Use SHKBP1 antibodies to immunoprecipitate protein complexes

  • Probe for components of both EGFR and inflammatory signaling pathways

  • Compare complex formation under different stimulation conditions

• Knockdown/overexpression studies:

  • Manipulate SHKBP1 levels and assess impact on inflammatory responses

  • Measure inflammatory cytokine production (e.g., IL-1β, IL-6, TNF-α)

  • Evaluate effects on inflammatory transcription factors like STAT1

• Phosphorylation analysis:

  • Use SHKBP1 antibodies in combination with phospho-specific antibodies

  • Track activation status of signaling nodes that might integrate EGFR and inflammatory pathways

  • Consider potential SHKBP1 phosphorylation under different conditions

• Temporal dynamics:

  • Perform time-course experiments following stimulation

  • Use SHKBP1 antibodies to track changes in protein complexes over time

  • Determine if SHKBP1's role changes during acute versus chronic inflammatory responses

How might single-cell analysis techniques incorporate SHKBP1 antibodies for advanced research applications?

Single-cell analysis with SHKBP1 antibodies offers promising research opportunities:

• Single-cell imaging:

  • Use high-resolution imaging with SHKBP1 antibodies to analyze subcellular localization

  • Implement live-cell imaging with cell-permeable labeled antibody fragments

  • Apply super-resolution microscopy to visualize nanoscale protein-protein interactions

• Mass cytometry (CyTOF):

  • Incorporate metal-conjugated SHKBP1 antibodies into CyTOF panels

  • Simultaneously measure SHKBP1 levels alongside multiple signaling markers

  • Identify cell subpopulations with distinct SHKBP1 expression/function

• Single-cell Western blotting:

  • Use SHKBP1 antibodies in microfluidic single-cell Western blot systems

  • Correlate SHKBP1 expression with other proteins at single-cell resolution

  • Identify rare cell populations with altered SHKBP1 expression

• Spatial transcriptomics integration:

  • Combine SHKBP1 immunostaining with spatial transcriptomics

  • Correlate protein localization with gene expression patterns

  • Map SHKBP1 function within tissue microenvironments

• Methodological considerations:

  • Optimize antibody concentration for single-cell applications (typically higher than bulk assays)

  • Validate specificity rigorously in single-cell contexts

  • Develop computational pipelines for integrating antibody-based data with other single-cell datasets

What are the methodological considerations for using SHKBP1 antibodies in studying protein degradation pathways?

For studying protein degradation pathways:

• Pulse-chase experiments:

  • Use SHKBP1 antibodies to track protein stability over time

  • Compare degradation rates of SHKBP1 versus its binding partners

  • Assess how manipulating SHKBP1 affects EGFR degradation

• Ubiquitination analysis:

  • Immunoprecipitate SHKBP1 under denaturing conditions

  • Probe for ubiquitin to assess SHKBP1 ubiquitination status

  • Determine if SHKBP1 affects ubiquitination of CIN85 or EGFR

• Proteasome/lysosome inhibition studies:

  • Treat cells with proteasome or lysosome inhibitors

  • Use SHKBP1 antibodies to monitor accumulation patterns

  • Determine degradation pathway specificity

• Fluorescence-based degradation assays:

  • Create fluorescent protein fusions and validate with antibodies

  • Track degradation kinetics in live cells

  • Correlate with endogenous protein behavior using antibodies

• Methodological optimization:

  • Include appropriate controls for protein synthesis inhibition

  • Account for potential effects of tags on degradation dynamics

  • Consider cell type-specific differences in degradation machinery